welcome to Treatment strategy of Chinese thrombosis disease!

Home > News > Latest Research

Canada warns of the risk of venous thromboembolism in cisplatin

2017-08-05

Not long ago, the Canadian Department of Health website posted information to alert cisplatin to venous thromboembolism risk. The safety assessment is based on foreign regulators issued by the prescription update information began to start. Cisplatin is an anti-tumor drug that is used in combination with other therapies for the treatment of advanced bladder, testis and ovarian cancer. Listed in Canada in 1979, only available through prescription. In the Canadian market, there are five kinds of cisplatin for the common name of the product sales, are 1 mg / mL specifications of the intravenous injection, the capacity of 10 mL, 50 mL and 100 mL. The Canadian Department of Health has received 18 reports of venous thrombosis associated with cisplatin use. All cases were identified as likely to be associated with cisplatin. Of the reported cases, five reported death outcomes but were unable to determine the cause of death based on the information provided in the adverse event report. Cancer patients have a higher risk of venous thromboembolism and associated fatal complications. At the same time, there are 520 cases of venous thromboembolism associated with cisplatin in the WHO database. In addition, the frequency of venous thrombosis in patients treated with cancer was evaluated in a published study. It was concluded that the risk of venous thromboembolism in patients treated with cisplatin was higher than that of non-cisplatin. The Canadian Department of Health has considered the issue of the use of cisplatin in the treatment of advanced bladder, testis and ovarian cancer with increased risk of venous thrombosis. It is recommended that all cisplatin manufacturers in Canada update the prescription information for products and incorporate warnings about increased risk of venous thromboembolism. (China News)

Return List